Crossmark

ASO Author Reflections: Neoadjuvant Chemotherapy Prior to CRS/HIPEC for Metachronous Colorectal Peritoneal Metastases: No Survival Gain and Increased Perioperative Risk

Crossref DOI link: https://doi.org/10.1245/s10434-026-19646-6

Published Online: 2026-04-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bank, Hannah

Wach, Michael M.

Ongchin, Melanie
License Information

Text and Data Mining valid from 2026-04-22

Version of Record valid from 2026-04-22
More Information

Article History

Received: 27 March 2026

Accepted: 27 March 2026

First Online: 22 April 2026

Disclosure

: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no conflicts of interest to disclose. It was presented orally at the 2024 Advanced Cancer Therapies meeting in San Juan, Puerto Rico and as a poster at the 2024 Society of Surgical Oncology meeting in Atlanta, GA.

Document is current

Any future updates will be listed below